


Valpromide

Cat. No.:	HY-B2117		
CAS No.:	2430-27-5		
Molecular Formula:	C ₈ H ₁₇ NO		
Molecular Weight:	143.23		
Target:	HSV; Epoxide Hydrolase		
Pathway:	Anti-infection; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (349.09 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	6.9818 mL	34.9089 mL	69.8178 mL
	5 mM	1.3964 mL	6.9818 mL	13.9636 mL
	10 mM	0.6982 mL	3.4909 mL	6.9818 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (17.45 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (17.45 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (17.45 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Valpromide is an amide derivative of valproic acid and inhibits human epoxide hydrolase.

IC₅₀ & Target

epoxide hydrolase^[1]

REFERENCES

[1]. Pacifici GM, et al. Valpromide inhibits human epoxide hydrolase. Br J Clin Pharmacol. 1986 Sep;22(3):269-74.

[2]. Gorres KL, et al. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus. MBio. 2016 Mar 1;7(2):e00113.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA